Lymphoma Rounds and Panel Discussion: Frontline Decision-Making for Aggressive Lymphoma

Jointly provided by

        

Support for this activity has been provided through educational grants from AbbVie, Inc.; Acrotech Biopharma; ADC Therapeutics; AstraZeneca; BeOne Medicines USA, Inc.; Bristol Myers Squibb; Genmab; Incyte; Kite Pharma, Inc.; Pfizer; Secura Bio; SERB Pharmaceuticals.

This activity is supported by the following exhibiting sponsors: Acrotech Biopharma, Adaptive Biotechnologies, Arima Genomics, BeOne Medicines USA, Inc., Incyte, Merck, Pfizer.

Release date: 3/13/2026

Expiration date: 3/13/2027

Estimated time to complete: 0.75 hour

Overview

The Lymphoma Rounds Symposium program provides a forum for practicing physicians from academic and community medical centers to meet throughout the academic year and address issues specific to the diagnosis and treatment of their lymphoma patients. In this program, physicians can network, share best practices, and learn the latest information on new therapies and advances in lymphoma management through interactive case studies presented by lymphoma experts.

This activity reviews management of limited-stage aggressive B-cell lymphoma, including response-adapted strategies based on level of disease risk. In the panel discussion that follows, clinicians from a variety of practice settings discuss how they are integrating emerging circulating tumor DNA assays to complement end-of-therapy management.

Faculty

John Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Paolo Caimi, MD
Cleveland Clinic
Cleveland, Ohio

Changchun (George) Deng, MD, PhD
University Hospitals Cleveland
Cleveland, Ohio

Janna Minehart, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Mark Roschewski, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen Schuster, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Ariel Sindel, DO
University Hospitals Cleveland
Cleveland, Ohio

Koen van Besien, MD, PhD
University Hospitals Cleveland
Cleveland, Ohio

Target Audience

This activity has been designed to meet the educational needs of practicing physicians from academic and community medical centers.

Learning Objectives

After completing this activity, participants should be better able to: 

  • Summarize the latest developments in lymphoma diagnosis, treatment, and management
  • Apply best practices for treating lymphoma patients
  • Inform patients about potential clinical trial opportunities
  • Establish a network of health care professionals who work with lymphoma patients

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Lymphoma Research Foundation, and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months.

All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, reselling, or distributing health care products used by or on patients.


All relevant relationships have been mitigated. The following disclosures were made:

John Burke, MD, has disclosed the following relevant financial relationships:
Consultant: AbbVie, AstraZeneca, BeiGene, BMS, Genentech, Novartis, Regeneron

Paolo Caimi, MD, has disclosed the following relevant financial relationships:
Advisor/review panel participant: ADC Therapeutics, AbbVie, Autolus, BMS, Genmab, Genentech, Novartis

Changchun Deng, MD, PhD, has disclosed the following relevant financial relationships: 
Speaker: BeOne 
Common stock: ADCT, Pfizer 
Retirement account: Johnson & Johnson 

Janna Minehart, MD, has disclosed no relevant financial relationships.

Mark Roschewski, MD, has disclosed no relevant financial relationships.

Stephen Schuster, MD, has disclosed the following relevant financial relationships:
Consultant: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene/BeOne Therapeutics, Caribou Bio, Chugai, Fosun Kairos, Janssen, Novartis

Ariel Sindel, DO, has disclosed the following relevant financial relationships:
Speakers Bureau: Incyte

Koen van Besien, MD, PhD, has disclosed the following relevant financial relationships:
Stock: Avertix, Hemogenyx
Data and Safety Monitoring Board: ADC Therapeutics, Autolus

University of Cincinnati
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Lymphoma Research Foundation
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd; the University of Cincinnati; the Lymphoma Research Foundation; AbbVie, Inc.; Acrotech Biopharma; ADC Therapeutics; AstraZeneca; BeOne Medicines USA, Inc.; Bristol Myers Squibb; Genmab; Incyte; Kite Pharma, Inc.; Pfizer; Secura Bio; and SERB Pharmaceuticals do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd; the University of Cincinnati; the Lymphoma Research Foundation; AbbVie, Inc.; Acrotech Biopharma; ADC Therapeutics; AstraZeneca; BeOne Medicines USA, Inc.; Bristol Myers Squibb; Genmab; Incyte; Kite Pharma, Inc.; Pfizer; Secura Bio; or SERB Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest and program evaluation. Certificates can be printed immediately.

Contact Information

For questions regarding CME credit, contact University of Cincinnati at uc-cloudcme@uc.edu. 

For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.


Hardware/Software Requirements

  • iPad, iPad Mini, iPhone, or Android devices with an Internet connection and running current available OS
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge
    • Internet browsers (Mac): Chrome, Firefox, Safari

Privacy

This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by the University of Cincinnati. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the University of Cincinnati so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through the University of Cincinnati or RedMedEd. For more information, contact University of Cincinnati at uc-cloudcme@uc.edu or RedMedEd at education@redmeded.com.

For more information about the privacy policy of the University of Cincinnati, please visit https://www.uc.edu/about/privacy.html.

Copyright

© 2026. This CME/CE-certified program is held as copyrighted by the University of Cincinnati, the Lymphoma Research Foundation, and RedMedEd. Through this notice, the University of Cincinnati, the Lymphoma Research Foundation, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.